Biotech entity
Bhavin Mehta is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.7 stories per week across a 19-day span. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: Aug 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Bhavin Mehta is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.7 stories per week across a 19-day span. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. The 6.5 average consequence score is above the beat benchmark of 5.6 in the same window. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Medicines and Healthcare products Regulatory Agency appears in 2 tracked Biotech stories published from July 27, 2026 through August 14, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 134 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Medicines and Healthcare products Regulatory Agency. Shared-story counts are live from our verified record — not editorial picks.
Interim 3-year overall survival data expected
Company expects to announce interim 3-year overall survival data from the Phase 2b OST-HER2 trial in early September 2026.
FDA Type C Statistical Methods Meeting
Meeting expected in mid-September 2026 with CBER to review statistical methods, comparator appropriateness, RMAT designation, and rolling review.
MHRA Scientific Advice Meeting
UK MHRA meeting expected in September 2026 to review statistical methods supporting the CMAA, including finalization with 2.5-year overall survival.
Company announces FDA Type C meeting and MHRA parallel review
OS Therapies announces FDA granted Type C Statistical Methods Meeting to review 2.5-year OS data for OST-HER2; MHRA Scientific Advice Meeting granted in parallel.
Biotech stakeholders are watching OST-HER2's FDA Type C meeting because the statistical comparator decision could de-risk or delay a rare oncology asset. With 3-year survival data due days earlier and MHRA engagement in parallel, the event sequence is a near-term catalyst.
Source: The Kingston Whig Standard · Financialcontent
The zero-tariff India-UK trade pact propels Indian pharmaceutical exports to a projected $981M, offering biotech and pharma firms expanded market access, lower costs, and new collaboration channels in R&D and manufacturing.
Source: indiagazette.com · britainnews.net
Medicines and Healthcare products Regulatory Agency is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
